Detection of Residual HCV RNA in Patients Who Have Achieved Sustained Virological Response Is Associated with Persistent Histological Abnormality

Background & Aims: This study aimed to assess the changes in platelet counts of patients with liver cirrhosis due to chronic HCV, who achieved sustained virological response (SVR) after taking direct acting antivirals (DAAs) in a large cohort study in Egypt. Methods: This multicenter observational retrospective study was carried out on 2500 chronic hepatitis C virus (HCV) infected patients who achieved (SVR) after treatment with direct acting antiviral drugs (DAA). HCV infection was confirmed by positive PCR for HCV RNA infection. SVR was defined as a negative PCR test for HCV-RNA 12 weeks after completion of DAA therapy. Platelets count was measured before therapy, during therapy, at the end of treatment, and 12 weeks after the end of the treatment. Results: There were 2186 patients enrolled in the study; 1866 (85.4%) were treatment naïve. There were 1006 (46%) males and 1180 (54%) females. Mean age was 50.82± 11.66 years, 2142 (98 %.0) patients achieved SVR, 2118 (96.9%) patients had Child -Pugh class A cirrhosis, and 68 (3.1%) had Child -Pugh class B liver cirrhosis. A significant increase of the platelets count was detected at the end of treatment in comparison to the pretreatment levels (P<0.001), and after achieving SVR (P <0.001) when compared to the pretreatment values. Conclusion: Improvement of platelets count occurs after HCV therapy with DAAS in patients with liver cirrhosis. These results suggested that HCV eradication may have a role in improvement of platelet count.

Download Full-text

Assessment of Doppler haemodynamic changes suggestive of portal hypertension in cirrhotic HCV patients after sustained virological response to direct antiviral agents

QJM ◽

10.1093/qjmed/hcab100.024 ◽

2021 ◽

Vol 114 (Supplement_1) ◽

Author(s):

Mennatullah M Ezzat ◽

Sara M Abdelhakam ◽

Amira M Al-Balakosy ◽

Ahmed A Ghalwash

Keyword(s):

Portal Hypertension ◽

Sustained Virological Response ◽

Virological Response ◽

Antiviral Agents ◽

Liver Stiffness ◽

University Hospital ◽

Core Antigen ◽

Hcv Rna ◽

Haemodynamic Changes ◽

Direct Antiviral Agents

Abstract Background Egypt has the highest prevalence rate of HCV in the world. About 14.7% of the Egyptian people have HCV antibodies and 9.8% have an active infection. The death rate due to liver disease about 40,000 each year (near10% of all deaths). It is the second after the cardiac diseases. Aim of Work to assess Doppler haemodynamic changes suggestive of portal hypertension in cirrhotic HCV Egyptian patients after sustained virological response to direct antiviral agents, and their correlation with liver stiffness measurements by Fibroscan. Patients and Methods This prospective cohort study was conducted at Viral Hepatitis Unit at Ain Shams University Hospital and Al-Agouza Police Hospital during the period from May 2018 to July 2019. The study included 50 Egyptian treatment-naïve chronic hepatitis C patients with cirrhosis on Sofosbuvir, Daclatasvir for 12 weeks. Patients were subjected to history and full physical examination, radiology assessment (Abdominal Ultrasound and color Doppler), Upper GI endoscopy and Fibroscan before treatment and 6 months after treatment. Followed up with CBC, AST, ALT, Total bilirubin, Albumin, creatinine and Coagulation profile before and after 12 weeks of treatment And HCV RNA by PCR and HCV CORE Antigen before and then after 12 weeks of treatment. Results Treatment with sofosbuvir plus Daclatasvir for 12weeks resulted in undetectable HCV RNA by PCR in 100% of the patients at the end of treatment. There was a significant improvement in portal hemodynamics 6 months after treatment as well as a significant correlation between Doppler indices and fibroscan. Conclusion: Doppler portal hypertensive parameters, as a marker of portal hypertension, were improved in parallel with the improvement in fibroscan values after viral clearance and its improvement in the current study mandate urgent treatment to avoid possible complications.

Download Full-text

Efficacy of Weeks 4 and 12 Post-therapy HCV RNA Levels in Determining Sustained Virological Response [SVR] after Completing 24 or 48 Weeks of Telaprevir-based Triple Therapy for Chronic HCV Infection

The American Journal of Gastroenterology ◽

10.14309/00000434-201310001-00400 ◽

2013 ◽

Vol 108 ◽

pp. S119

Author(s):

Irfan Alam ◽

Shadi Giani ◽

Ammar Hassan

Keyword(s):

Triple Therapy ◽

Sustained Virological Response ◽

Virological Response ◽

Hcv Infection ◽

Hcv Rna ◽

Chronic Hcv Infection ◽

Chronic Hcv ◽

Post Therapy ◽

Rna Levels

Download Full-text

Age and Prediction of Sustained Virological Response to Hepatitis C Virus (HCV) Infection Treatment Based on 28‐Day Decrease in HCV RNA Levels

The Journal of Infectious Diseases ◽

10.1086/644507 ◽

2009 ◽

Vol 200 (9) ◽

pp. 1484-1485 ◽

Cited By ~ 6

Author(s):

Giorgio Antonucci ◽

Claudio Angeletti ◽

Francesco Vairo ◽

Maria Antonella Longo ◽

Enrico Girardi

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Sustained Virological Response ◽

Virological Response ◽

Hcv Infection ◽

Hcv Rna ◽

Infection Treatment ◽

Rna Levels

Download Full-text

VIROLOGICAL RESPONSES OF VELPATASVIR/SOFOSBUVIR IN PATIENTS WITH HCV GENOTYPE 3

Journal of University Medical & Dental College ◽

10.37723/jumdc.v11i1.397 ◽

2020 ◽

Vol 11 (1) ◽

pp. 9-14

Author(s):

Muhammad Sarfraz ◽

Arshad Rabbani ◽

Muhammad Shahzad Manzoor ◽

Benish Adil

Keyword(s):

Treatment Response ◽

Sustained Virological Response ◽

Virological Response ◽

Hcv Rna ◽

Rapid Virological Response ◽

Genotype 3 ◽

Hcv Genotype ◽

End Of Treatment ◽

Treatment Naïve ◽

Hcv Genotype 3

BACKGROUND & OBJECTIVE: The role of Velpatasvir/Sofosbuvir in the treatment of hepatitis C virus type 3 infection is evaluated in terms of virologic responses. i.e Rapid Virological Response (RVR) End of treatment response (ETR) and Sustained virological response (SVR 12). METHODOLOGY: This was a descriptive case study conducted in Liver OPD of Benazir Bhutto Hospital during 01 November 2018 to 30 April 2019 , in which 100 patients of HCV were enrolled, all of them had HCV genotype 3 infection. Every patient was treated with combination of Velpatasvir/Sofosbuvir 100mg/400 mg Once Daily as part of treatment regimen of HCV infection for 12 weeks. Pre-treatment HCV RNA QUANTITATIVE PCR was done, which was repeated on 4, 12 weeks of treatment and then 12 weeks post treatment. RESULTS: Among 100 patients, 51 (51%) were male and 49 (49%) were females. Mean age of patients was 43.2 ± 10.4 years (mean ± SD). Mean BMI of enrolled patients was 21.34 ± 2.40 kg/m2. 33% patients were cirrhotic while 67% were non cirrhotic. 53% patients were treatment experienced while 47% were treatment naïve. Rapid Virological Response (RVR) was achieved in 92%, End of treatment response (ETR) was achieved in 96%, while Sustained Virological response (SVR12) was achieved in 99% patients. The results were stratiﬁed according to age, gender and BMI. There was no eﬀect of these parameters on the ﬁnal results. CONCLUSION: Virological response (RVR, ETR, SVR12) of Velpatsvir /Sofosbuvir and Ribavirin is encouraging.

Download Full-text

Favorable Outcomes of Chinese HCV-Related Cirrhotic Patients with Sustained Virological Response after Pegylated Interferon Plus Ribavirin Treatment

BioMed Research International ◽

10.1155/2017/8061091 ◽

2017 ◽

Vol 2017 ◽

pp. 1-8

Author(s):

Geng-lin Zhang ◽

You-ming Chen ◽

Ting Zhang ◽

Qing-xian Cai ◽

Xiao-hong Zhang ◽

...

Keyword(s):

Sustained Virological Response ◽

Virological Response ◽

Clinical Course ◽

Laboratory Data ◽

Pegylated Interferon ◽

Liver Function Tests ◽

Hcv Rna ◽

Pegylated Interferon Plus Ribavirin ◽

Cirrhotic Patients

Few studies have conducted follow-up investigations of the clinical course in HCV-related cirrhotic patients who achieved a sustained virological response (SVR) with pegylated interferon plus ribavirin treatment (PegIFN + RBV). We investigated the clinical course and laboratory data in a prospective cohort study enrolling HCV-related cirrhotic patients who received PegIFN + RBV between August 2008 and July 2013 in China. Complete blood counts, liver function tests, and HCV-RNA were serially examined. Liver-related complications were recorded. To detect hepatocellular carcinoma (HCC), alpha-fetoprotein assays, and ultrasound scans were repeated at 6-month intervals. Twenty-five patients were enrolled, including 8 patients with decompensation events before treatment. Eighteen patients achieved SVR with a mean follow-up period of 25.78 months. During the follow-up period, only one patient exhibited HCV-RNA positivity and no decompensation events were detected, but 4 patients developed HCC after SVR. APRI decreased more in patients with SVR than in patients with non-SVR (median, −1.33 versus 0.86,P<0.001). The albumin levels and platelet counts significantly increased during the follow-up period after SVR (44.27±4.09versus42.63±4.37,P=0.037and173.89±87.36versus160.11±77.97,P=0.047). These data indicated that HCV-related cirrhotic patients with SVR after PegIFN + RBV may have a favorable clinical course and improvements in laboratory data. Moreover, HCC should be monitored.

Download Full-text